

## Original Research Article

# Clinical efficacy of dexmedetomidine in two different doses to attenuate the hemodynamic changes during laparoscopic cholecystectomy

Tahir Ahamad Masoori, Kumkum Gupta\*, Salony Agarwal, Manoranjan Bansal, Azka Zuberi, Abdul Samad

Department of Anaesthesiology and Critical Care, Subharti Medical College, Meerut, Uttar Pradesh, India

**Received:** 07 January 2018

**Accepted:** 03 February 2018

**\*Correspondence:**

Dr. Kumkum Gupta,

E-mail: [Kumkumprashant75@gmail.com](mailto:Kumkumprashant75@gmail.com)

**Copyright:** © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

### ABSTRACT

**Background:** Laryngoscopy and laparoscopy lead to predictable hemodynamic changes. Dexmedetomidine is selective 2 agonist with dose dependent sedation, sympatholysis and analgesia, hence could provide stable hemodynamics during laparoscopic surgeries. The present study was aimed to compare the clinical efficacy of dexmedetomidine infusion in two different doses to attenuate the hemodynamic variations during laparoscopic cholecystectomy.

**Methods:** Total 60 adult patients of ASA physical status I and II of both gender, scheduled for elective laparoscopic cholecystectomy, were randomly allocated into two groups of 30 patients. All patients were infused with loading dose of dexmedetomidine (1µg/kg) before induction. Patients of Group 1 received maintenance infusion of dexmedetomidine in doses of 0.3µg/kg/h and patients of Group 2 received maintenance infusion of dexmedetomidine in doses of 0.6µg/kg/h, continued till the end of surgery. Heart rate and blood pressure were recorded preoperatively, after dexmedetomidine administration, after induction, intubation, after creation of pneumoperitoneum and postoperatively. Intraoperative changes in heart rate and blood pressure were noted as primary variables and dexmedetomidine related side effects were noted as secondary outcomes, for statistical analysis.

**Results:** The hemodynamic responses were attenuated in patients of both groups after laryngoscopy, intubation and creation of pneumoperitoneum but patients of Group 2 (0.6µg/kg/h) showed more stability in hemodynamics. The difference between the group was statistically significant (p value=0.001). No any evident complication or side effects occurred.

**Conclusions:** Dexmedetomidine infusion was effective for attenuating the hemodynamic changes due to laryngoscopy and laparoscopy but were better with maintenance infusion of dexmedetomidine in dose of 0.6µg/kg/h.

**Keywords:** Dexmedetomidine, Hemodynamic changes, Laryngoscopy, Laparoscopic cholecystectomy, Pneumoperitoneum

### INTRODUCTION

Laparoscopic cholecystectomy is advantageous due to cosmetically small scar, less postoperative pain, shorter hospital stays and early ambulation, but pneumoperitoneum leads to increase in plasma catecholamine levels, resulting increase in systemic and pulmonary vascular resistance, rise in arterial pressure

and heart rate with reduced cardiac output. The reverse Trendelenberg position leads to significant hemodynamic and respiratory changes, thereby causing further reduction in cardiac output.<sup>1,2</sup> Laryngoscopy with intubation also lead to transient and variable hemodynamic changes along with reflex sympathetic stimulation leading to peripheral sympatho-adrenal response.<sup>3</sup>

The magnitude of hemodynamic changes can be decreased by using different medical interventions, but each drug has its own limitations.<sup>4,5</sup> Besides minimizing the cardiovascular response, the ideal agent must have rapid onset of action, be safe and convenient to administer with desirable duration of action and also should not affect the recovery.

Dexmedetomidine,  $\alpha$ -2 adrenergic agonist, inhibits the release of nor-epinephrine by presynaptic activation of the  $\alpha$ -2 adrenoceptor in the Locus coeruleus while postsynaptic activation of  $\alpha$ -2 adrenoceptor in the central nervous system resulted in decrease in sympathetic activity. Its intravenous use decreases the serum catecholamine levels by 90% and suppresses the hemodynamic response of laryngoscopy and laparoscopy. Dexmedetomidine, due to its various distinct properties, might be suitable medication during laparoscopic cholecystectomy.<sup>6-8</sup>

The present study was aimed to compare the clinical efficacy of two different dosages of dexmedetomidine infusion to attenuate the hemodynamic changes during laryngoscopy, intubation and creation of pneumoperitoneum during laparoscopic cholecystectomy.

## METHODS

After approval from Institutional Ethical Committee and written informed consent, 60 patients of American Society of Anesthesiologists (ASA) physical status I and II of either sex aged between 18 to 58 years, scheduled for elective laparoscopic cholecystectomy, were enrolled for the present double blind randomized study.

The patients suffering from cardio-pulmonary diseases, hepatic, renal or endocrinal disease, obesity, uncontrolled hypertension, any neurological disorder and patients with anticipated difficult airway or who required more than one attempt for intubation, were excluded from the studies. Patients with known hypersensitivity or drug allergies, taking any antihypertensive or antidepressant drugs, were also excluded from the study.

The total 60 patients were randomly assigned to two groups of 30 patients each, according to computer generated random number table. After the loading dose of dexmedetomidine (1.0 $\mu$ g/kg), patients of Group 1 were given maintenance infusion of dexmedetomidine in dose of 0.3 $\mu$ g/kg/h and patients of Group 2 were given maintenance infusion of dexmedetomidine in dose of 0.6 $\mu$ g/kg/h, continued till the end of surgery. Study drug preparation was done by an assistant who was blinded to the study protocol and was not involved for any data collection.

All patients underwent through preanesthetic evaluation along with relevant investigation. Patients were given tab alprazolam 0.25mg and tab ranitidine 150mg, the night

before surgery and were kept fasting for 6 hours prior to surgery.

On arrival to operation theatre, baseline values of heart rate, non-invasive systemic arterial pressure, peripheral oxygen saturation (SpO<sub>2</sub>) and electrocardiogram (ECG) were recorded and lactate Ringer solution was started at the rate of 4-6ml/kg/h. All patients received glycopyrrolate 0.2mg IM half an hour before surgery and midazolam 1mg and ondansetron 4mg, intravenously. The loading dose of dexmedetomidine 1 $\mu$ g/kg, diluted in 10 ml normal saline, was infused over 10 minutes. Patients of Group 1 were given infusion of dexmedetomidine 0.3 $\mu$ g/kg/h and patients of Group 2 were given infusion of dexmedetomidine 0.6 $\mu$ g/kg/h, continued till the end of surgery.

After preoxygenation, anesthesia was induced with fentanyl 2 $\mu$ g/kg and propofol 2mg/kg and direct laryngoscopy was facilitated by vecuronium bromide 0.1 mg/kg. All patients were intubated with proper sized cuffed endotracheal tube and any patient requiring more than 20 seconds or more than one attempt, was excluded from the study. Anesthesia was maintained with isoflurane, nitrous oxide 60% in oxygen and vecuronium 0.02 mg/kg. Pneumoperitoneum was created by insufflations of carbon dioxide (CO<sub>2</sub>) and intra-abdominal pressure was maintained at 12mmHg. They were mechanically ventilated to keep the normocapnia (EtCO<sub>2</sub> between 35-40mmHg). Patients were positioned in a 15° reversed Trendelenberg position and tilted towards the left side to facilitate exposure of the gall bladder.

After completion of surgery, patients were returned to supine position. Dexmedetomidine infusion was discontinued and residual neuromuscular blockade was antagonized by appropriate doses of neostigmine and glycopyrrolate and tracheal extubation was performed. The heart rate and arterial blood pressure were recorded at base line, after dexmedetomidine infusion, after induction and immediately after intubation. Then at regular intervals of 1<sup>st</sup> min, 2<sup>nd</sup> min, 3<sup>rd</sup> min, 4<sup>th</sup> min, 5<sup>th</sup> min, 7<sup>th</sup> min and 10<sup>th</sup> min, after tracheal intubation. Later on, these parameters were noted at regular intervals of 5 minutes till end of surgery and post extubation.

The hemodynamic changes observed as abnormal finding during the study were defined as hypotension when SBP <20% of baseline value or <90 mm of Hg, on two consecutive readings. Hypertension was defined as SBP >20% of baseline value or >140 mm Hg. Tachycardia was defined as heart rate >100 beats/min and bradycardia were defined as heart rate < 60 beats/min.

The intraoperative hypertension and tachycardia was managed by increasing the dial concentration of isoflurane and hypotension was primarily treated by increasing the infusion rate of lactate Ringer solution and infusion of study medication was discontinued.

Bradycardia was treated with intravenous atropine 0.5 mg bolus. Patients were transferred to post anesthesia care unit and monitored until there were no signs of any drug-induced effects. Any hemodynamic changes, respiratory depression, postoperative shivering, nausea and vomiting was noted and were treated accordingly.

**Sample size and statistical analysis**

Preliminary sample size was based on previous studies, which indicated that approximately 27 patients should be included in each group in order to ensure power of 80% and  $\alpha$ -error of 0.05 with confidence limit of 95% for detecting clinically meaningful reduction by 20% in heart rate and blood pressure during laryngoscopy and laparoscopy. Assuming a 5% drop out rate, a total of 60 patients were incorporated in the study for better validation of results. The variables were expressed as Mean  $\pm$ SD. The statistical analysis was done using Stat Graphics Centurion software version 17. The parameters were compared using the Chi-square test for categorical data, one-way analysis of variance (ANOVA) for intergroup comparison, and paired t-test for intragroup comparison. P-value <0.05 was considered statistically significant.

**RESULTS**

The present study was conducted on sixty adult patients of ASA physical status I and II of either sex. The

demographic parameters of age, weight, height, gender ratio and ASA physical status were comparable between both the groups (Table 1). Baseline mean systolic blood pressure, diastolic blood pressure, and heart rate in patients of both groups were comparable.

**Table 1: Demographic profile of the study population.**

Parameters	Group 1	Group 2	P value
Age (years)	41.77 $\pm$ 10.99	40.23 $\pm$ 8.7	0.54
Weight (kg)	59.17 $\pm$ 5.5	60.43 $\pm$ 9.3	0.525
Height(cm)	159.97 $\pm$ 3.8	160.83 $\pm$ 4.5	0.427
Gender (M/F)	18/12	21/9	0.659
ASA (I/II)	24/6	23/7	0.098

Data are presented as Mean  $\pm$  SD or absolute numbers. P value >0.05 is statistically insignificant

**Changes in heart rate**

The mean heart rate decreased significantly below the baseline value after starting the dexmedetomidine infusion. No further significant changes were noticed immediately after induction of anaesthesia. After intubation, the heart rate increased significantly above the baseline values in patients of Group 1 but heart rate did not increase in patients of Group 2. The difference between the groups showed statistically significant till 7<sup>th</sup> minute after intubation. Later on, the changes in mean heart rate were comparable between the groups (Table 2).

**Table 2: Changes in heart rate at different time intervals.**

Heart rate (beats/min)	Group 1		Group 2		P value
	Mean	Std. Deviation	Mean	Std. Deviation	
Baseline	98.64	13.21	97.88	11.70	0.029
After dexmedetomidine premedication	96.92	12.48	98.88	12.54	0.269
After induction	94.71	6.70	92.04	4.20	0.329
Just after intubation	93.71	8.70	91.04	5.28	0.846
1 min	90.12	7.07	90.01	8.02	0.392
2 min	87.96	7.08	87.6	7.01	0.396
3 min	85.32	7.71	77.36	7.30	0.0001**
4 min	85.76	7.66	73.12	6.35	0.0001**
5 min	83.12	6.28	72.4	5.32	0.0001**
7 min	84.4	8.22	72.92	6.71	0.0001**
10 min	83.92	5.46	83.84	5.12	0.451
15 min	87.96	7.08	87.6	7.01	0.564
20 min	86.32	7.47	76.36	7.40	0.0001**
30 min	85.6	7.61	74.12	6.36	0.0001**
45 min	83.12	6.28	82.4	5.32	0.393
60 min	89.71	8.92	82.04	5.28	0.795
75 min	80.22	7.07	80.14	8.10	0.465
90 min	87.96	7.08	87.6	7.01	0.555
Post extubation	86.32	7.47	86.16	7.40	0.657

Data are presented as Mean  $\pm$  SD. P value <0.001 is statistically highly significant

**Changes in systolic blood pressure**

After dexmedetomidine infusion, induction and intubation, there was a continuous gradual reduction in mean systolic blood pressure in patients of both groups with statistically highly significant difference at 1<sup>st</sup> min,

5<sup>th</sup> min, and 10<sup>th</sup> min following laryngoscopy and intubation (p=0.000).

After creation of pneumoperitoneum, the changes in mean systolic blood pressure were comparable between the groups till post extubation (Table 3).

**Table 3: Changes in systolic blood pressure at different time intervals.**

Systolic BP (mmHg)	Group 1		Group 2		P value
	Mean	Std. Deviation	Mean	Std. Deviation	
Baseline	134	9.9	136	9.2	0.413
After dexmedetomidine premedication	131	10.7	131	10.0	0.532
After induction	129	7.3	126	7.4	0.0001***
Just after intubation	130	6.4	126	6.2	0.0001**
1 min	130	7.8	124	7.2	0.0001**
2 min	129	7.6	123	7.3	0.0001**
3 min	130	6.2	126	7.4	0.0001**
4 min	129	7.1	123	6.5	0.0001**
5 min	122	11.6	122	9.5	0.438
7 min	121	10.8	120	9.0	0.582
10 min	128	7.4	122	6.7	0.0001**
15 min	130	7.4	126	6.5	0.0001**
20 min	122	11.2	121	8.1	0.857
30 min	121	11.6	122	8.5	0.985
45 min	121	10.8	120	9.0	0.191
60 min	120	9.4	118	8.8	0.664
75 min	120	10.7	118	9.5	0.489
90 min	122	11.2	121	8.1	0.958
Post extubation	122	12.5	124	9.9	0.854

Data are presented as Mean ± SD. P value <0.001 is statistically highly significant

**Table 4: Changes in diastolic blood pressure at different time intervals.**

Diastolic BP (mm hg)	Group 1		Group 2		P value
	Mean	Std. Deviation	Mean	Std. Deviation	
Baseline	81.8	7.8	82.73	7.0	0.958
After dexmedetomidine premedication	88.2	8.7	81.47	7.7	0.155
After induction	80.27	7.8	72.4	6.9	0.0001**
Just after intubation	77.27	7.8	71.4	6.9	0.0001**
1 min	78.31	8.2	72.33	6.2	0.0001**
2 min	77.73	6.3	72.87	6.1	0.0001**
3 min	76.27	6.8	75.47	6.2	0.931
4 min	76.8	6.8	75.2	5.7	0.463
5 min	75.07	7.8	74.4	4.8	0.110
7 min	77.53	7.2	73.9	6.1	0.0001**
10 min	77.03	8.0	73.73	6.6	0.0001**
15 min	74.67	6.1	71.73	6.3	0.946
20 min	74.67	6.2	73	7.9	0.931
30 min	78.07	6.0	74.4	6.7	0.626
45 min	79.8	5.7	77	5.6	0.611
60 min	80.94	6.9	74.2	5.2	0.601
75 min	81.06	7.0	72.1	6.2	0.527
90 min	74.67	6.2	73.1	7.9	0.789
Post extubation	74.7	6.2	73.1	7.8	0.491

Data are presented as Mean ± SD. P value <0.001 is statistically highly significant

**Changes in diastolic blood pressure**

There was a gradual decrease in diastolic blood pressure after administration of dexmedetomidine, after induction and intubation with statistically significant difference between the groups, but after creation of pneumoperitoneum and post extubation, the fall in diastolic blood pressure was comparable between the groups (Table 4).

**Changes in mean arterial pressure**

There was significantly lower mean arterial pressure in patients of Group 2 when compared to Group 1, after induction, till 2<sup>nd</sup> minutes after intubation and then after 30<sup>th</sup> min till post extubation (Table 5).

**Table 5: Changes in mean arterial pressure at different time intervals.**

Mean arterial pressure (mmHg)	Group 1		Group 2		P value
	Mean	Std. Deviation	Mean	Std. Deviation	
Baseline	89.47	7.6	92.83	7.5	0.985
After dexmedetomidine premedication	87.33	8.4	90.97	7.2	0.699
After induction	89.5	8.7	79.37	8.2	0.001**
Just after intubation	89.5	8.4	81.37	8.1	0.001**
1 min	85.1	8.4	77.6	7.5	0.001**
2 min	83.5	7.0	78.47	6.9	0.001**
3 min	80.97	7.5	79.7	8.3	0.687
4 min	79.1	7.8	77.6	7.1	0.126
5 min	78.07	7.0	78.4	7.8	0.577
7 min	78.57	7.3	77.4	8.0	0.207
10 min	79.1	6.7	77.2	7.0	0.855
15 min	79.97	7.8	77.3	7.8	0.351
20 min	80.57	7.5	77.13	7.5	0.187
30 min	86.6	8.3	79.7	8.4	0.001**
45 min	89.3	7.4	77.6	7.5	0.001**
60 min	90.1	9.1	78.47	6.9	0.001**
75 min	88.2	8.9	79.7	8.3	0.001**
90 min	87.42	7.3	77.6	7.1	0.001**
Post extubation	88.11	9.4	78.57	8.1	0.001**

Data are presented as Mean  $\pm$  SD. P value <0.05 is statistically significant, P value <0.001 is statistically highly significant

**Adverse events**

Two patients of Group 2 developed bradycardia (Heart Rate =55beats/min), which occurred just after the dexmedetomidine infusion (0.6 $\mu$ g/kg/h), but it increased after laryngoscopy, so no treatment was given. There were no other postoperative complications related to dexmedetomidine or anesthetic technique occurred during study period.

**DISCUSSION**

Pneumoperitoneum during laparoscopic cholecystectomy leads to complex pathophysiological changes including significant hemodynamic variation and pulmonary physiology which compromise tissue perfusion. Direct laryngoscopy and intubation also leads to a hypertensive pressor response due to reflex sympathetic discharge. Though these hemodynamic changes are short lived but may be undesirable in patients with preexisting myocardial or cerebral insufficiency. Tachycardia is poorly tolerated in patients with coronary heart disease. Moreover, the reverse Trendelenberg position during

laparoscopic cholecystectomy further enhance the cardiovascular and pulmonary function.<sup>9</sup>

The pharmacological approach is appropriate for attenuation of hemodynamic changes during laparoscopic surgery. Opioid analgesics, intravenous lidocaine, beta adrenergic blockers,  $\alpha$ 2 adrenergic receptor agonists, and vasodilators were studied to attenuate these hemodynamic events.<sup>4</sup>

Dexmedetomidine is highly selective  $\alpha$ 2-adrenergic receptor agonist with a shorter duration of action. It minimizes the increase in heart rate and blood pressure by decreasing the central sympathetic outflow, thus modify the intraoperative cardiovascular responses to laryngoscopy and laparoscopic surgical stimuli. The significance of study lies in the fact that, which dosages of dexmedetomidine infusion could safely and effectively attenuate the hemodynamic changes, neither affecting the duration or modality of the anaesthetic technique nor has any effect on the recovery of patients. Dexmedetomidine in doses of 0.3 $\mu$ g/kg, 0.4 $\mu$ g/kg, 0.5 $\mu$ g/kg, 0.6 $\mu$ g/kg, 0.8 $\mu$ g/kg and 1 $\mu$ g/kg have been studied by various

authors to find the effective and safe dose but with conflicting results.<sup>10-12</sup>

For the present study, two different doses of dexmedetomidine infusion (0.3µg/kg/h and 0.6µg/kg/h) were chosen, to be given after loading dose of dexmedetomidine (1µg/kg) which was administered slowly over 10 minutes. Rapid administration of initial loading dose of dexmedetomidine was avoided to prevent the transient increase in blood pressure and reflex decrease in heart rate.

The primary action of dexmedetomidine on heart is negative chronotropic effect by blocking the cardio-accelerator nerves as well as by augmenting the vagal nerve. The decrease in heart rate can be attributed to reflex response for transient hypertension during initial part of infusion and subsequently it was due to diminish nor-epinephrine release and inhibition of central sympathetic outflow.<sup>13,14</sup>

In the present study, there was a gradual reduction in heart rate after dexmedetomidine administration in patients of both groups with no significant difference. After induction, there was decrease in systemic blood pressure in all patients, but the decrease was more in patients who received dexmedetomidine infusion in higher dose (0.6µg/kg/h), with statistically significant difference. Other workers also observed the similar results.

After intubation, there was increase in mean heart rate in patients of both groups which can be attributed to the increase in the central sympathetic outflow. Dexmedetomidine was effective for suppressing the rise in heart rate. The results of present study are similar with the studies conducted by Kunisawa et al and Sagioglu et al.<sup>15,16</sup> They stated that dexmedetomidine infusion blunts the hemodynamic changes of intubation and higher doses of dexmedetomidine caused greater reduction in the heart rate.

After creation of pneumoperitoneum, the changes in heart rate showed statistically significant difference between both the groups at 20minute. The present study was in accordance with the studies done by Basar et al.<sup>17</sup>

Bhattacharjee et al evaluated the efficacy of dexmedetomidine in patients undergoing laparoscopic cholecystectomy. They observed significantly lower mean arterial pressure and heart rate in patients of dexmedetomidine group after intubation and throughout the period of pneumoperitoneum. Dexmedetomidine has improved the intra and post-operative hemodynamic stability during laparoscopic surgery without prolongation of recovery.<sup>18</sup> The present study was in accordance of their study.

Yildiz M et al and Varshali MK et al studied the effect of dexmedetomidine on hemodynamic responses to

laryngoscopy, intubation and on anesthetic requirement.<sup>19,20</sup> They concluded that increase in blood pressure and heart rate were significantly lower in dexmedetomidine group than in placebo group. Sajith et al showed statistically significant difference in systolic, diastolic and mean arterial pressure between dexmedetomidine group and control group at 1<sup>st</sup>, 3<sup>rd</sup>, and 5<sup>th</sup> minute post extubation in their study.<sup>21</sup>

Bakhamees HS et al studied the effect of dexmedetomidine on morbidly obese adult patients, undergoing laparoscopic gastric bypass, by giving 0.8µg/kg bolus of dexmedetomidine, followed by dexmedetomidine infusion in dose of 0.4µg/kg/h. They concluded that the intraoperative infusion offered a better control of intraoperative and postoperative hemodynamics.<sup>22</sup>

The results of the present study were in accordance with these previous clinical studies. They all found significant difference in fall in heart rate and systolic blood pressure in patients who received intraoperative dexmedetomidine infusion in higher dosages.

Dexmedetomidine has offered a unique pharmacological profile with sedation, analgesia, sympatholysis and cardiovascular stability by attenuating the stress induced sympatho-adrenal responses to intubation and pneumoperitoneum during surgery.

## CONCLUSION

The present study concluded that dexmedetomidine infusion in dose of 0.6µg/kg/h, after the loading dose of dexmedetomidine (1µg/kg), appeared to be significantly more effective for attenuating the hemodynamic changes of laryngoscopy, tracheal intubation and pneumoperitoneum during laparoscopic cholecystectomy.

*Funding: No funding sources*

*Conflict of interest: None declared*

*Ethical approval: The study was approved by the Institutional Ethics Committee*

## REFERENCES

1. Westerband A, Van De Water, Amzallag M, Lebowitz P. Cardiovascular changes during Laparoscopic Cholecystectomy. *Surg Gynecol Obs.* 1992;175:535-8.
2. Joris JL, Noirot DP, Legrand MJ, Jacquet NJ, Lamy ML. Hemodynamic changes during laparoscopic cholecystectomy. *Anesthesia analgesia.* 1993;76(5):1067-71.
3. Stoelting RK. Circulatory changes during direct laryngoscopy and tracheal intubation: Influence of duration of laryngoscopy with or without prior lignocaine. *Anaesthesiology.* 1977; 7:381.
4. Helfman SM, Gold MI, Delisser EA, Herrington CA. Which drug prevents tachycardia and

- hypertension associated with tracheal intubation: lidocaine, fentanyl, or esmolol? *Anesth Analg.* 1991;73:502-04.
5. Carollo DS, Nossaman BD, Ramadhyani U. Dexmedetomidine: A review of clinical applications. *Curr Opin Anaesthesiol.* 2008;21:457-61.
  6. Scheinin B, Lindgren L, Randell T, Scheinin H, Scheinin M. Dexmedetomidine attenuates sympatho-adrenal responses to tracheal intubation and reduces the need for thiopentone and perioperative Fentanyl. *Br J Anaes.* 1991;68:126-31.
  7. Bloor BC, Ward DS, Belleville JP, Maze M. Effects of intravenous dexmedetomidine in humans. II. Hemodynamic changes. *Anesthesiology.* 1992;77:1134-42.
  8. Sudheesh K, Harsoor SS. Dexmedetomidine in anaesthetic practice: A wonder drug? *Indian J Anaes.* 2011;55:323-4.
  9. Hashimoto S, Hashikura Y, Munnakata Y, Kawasaki S, Makuchi P. Changes in cardiovascular and respiratory system during laparoscopic cholecystectomy. *J Laparoendosc Surg.* 1993;3:535-9.
  10. Bekker A, Sturaitis M, Bloom M, Moric M, Golfinos J, Parker E, et al. Effect of Dexmedetomidine on perioperative hemodynamics in patients undergoing craniotomy. *Anaesthesia and Analgesia.* 2008;107:1340-7.
  11. Turan G, Ozgultekin A, Turan C, Dincer E, Yuksel G. Advantageous effects of dexmedetomidine on haemodynamic and recovery responses during extubation for intracranial surgery. *European J anaesthesiology.* 2008;25(10):816-20.
  12. Patel CR, Engineer SR, Shah BJ, Madhu S. Effect of intravenous infusion of dexmedetomidine on perioperative haemodynamic changes and postoperative recovery: A study with entropy analysis. *Indian J Anaesth.* 2012;56:542-6.
  13. Laha A, Ghosh S, Sarkar S; Attenuation of sympatho-adrenal responses and anesthetic requirement by dexmedetomidine. *Anesth Essays Res.* 2013;7:65-70.
  14. Gupta K, Bansal M, Gupta PK, Singh M, Agarwal S, Tiwari V. Dexmedetomidine premedication with three different dosages to attenuate the adverse haemodynamic responses of direct laryngoscopy and intubation: a comparative evaluation. *Ain-Shams J Anaesthesiol.* 2016;9:66-71.
  15. Kunisawa T, Nagata O, Nagashima M. Dexmedetomidine suppresses the decrease in blood pressure during anaesthetic induction and blunts the cardiovascular responses to tracheal intubation. *Journal of Clin Anaesth.* 2009;21:194-9.
  16. Sagirolu AE, Celik M, Orhon Z, Yuzer S, Sen B. Different doses of dexmedetomidine on controlling hemodynamic responses to tracheal intubation. *The Internet J Anaesth.* 2010;26:45-8.
  17. Basar H, Akpınar S, Doganci N, Buyukkocak U, Kaymak C, Sert O, et al. The effect of preanaesthetic single dose dexmedetomidine on induction, haemodynamic and cardiovascular parameters. *Journal of Clin Anaesth.* 2008;20:431-6.
  18. Bhattacharjee DP, Nayek SK, Dawn S, Bandopadhyay G, Gupta K. Effect of dexmedetomidine on hemodynamics in patients undergoing laparoscopic cholecystectomy-A Comparative study. *J Anaesth Clin Pharmacol.* 2010;26:45-48.
  19. Yildiz M, Tavlan A, Tuncer S, Reisli R, Yosunkaya A, Otelcioglu S. Effect of dexmedetomidine on haemodynamic responses to laryngoscopy and intubation. *Drugs in R & D.* 2006;7(1):43-52.
  20. Keniya VM, Ladi S, Naphade R. Dexmedetomidine attenuates sympathoadrenal response to tracheal intubation and reduces perioperative anaesthetic requirement. *Ind J anaesthesia.* 2011;55(4):352-7.
  21. Sulaiman S, Karthekeyan RB, Vakamudi M, Sundar AS, Ravullapalli H, Gandham R. The effects of dexmedetomidine on attenuation of stress response to endotracheal intubation in patients undergoing elective off-pump coronary artery bypass grafting. *Annals of cardiac anaesthesia.* 2012;15(1):39.
  22. Bakhamees HS, El-Halafawy YM, El-Kerdawy HM, Gouda NM, Altemyatt S. The effect of Dexmedetomidine in morbidly obese patients undergoing laparoscopic gastric bypass. *Middle East J Anaesthesiology.* 2007;19:537-51.

**Cite this article as:** Masoori TA, Gupta K, Agarwal S, Bansal M, Zuberi A, Samad A. Clinical efficacy of dexmedetomidine in two different doses to attenuate the hemodynamic changes during laparoscopic cholecystectomy. *Int J Res Med Sci* 2018;6:959-65.